Anthropic: Claude May Have Identified a New Enzymatic System

Anthropic attributes to its AI Claude the autonomous identification of an enzymatic system present in bacteriophages, which is related to the architecture of Crispr. The function of this system is not yet understood, and its potential uses remain uncertain. This announcement marks the first result from the company's wet lab and serves as a showcase for Claude's capabilities, set against a backdrop of scientific recruitment, ambitions in drug discovery, and preparations for an IPO.

Unknown Function and Uncertain Comparison to Crispr

The discovery announced by Anthropic remains shrouded in uncertainties: no concrete application has been demonstrated, and it is not established that it could have an impact comparable to Crispr technology. Anthropic clarifies that the function of the identified enzymatic system is not yet understood. Nevertheless, the company draws a connection between this discovery and the Crispr machinery and explains that it chose to share it early to illustrate Claude's capabilities and provide the scientific community with insight into its work.

Massive Screening by Claude Agents and Laboratory Validation

Anthropic reports that nearly 950 Claude agents analyzed a vast database of DNA sequences for 21 hours, processing 210 million tokens. Human intervention was limited to the initial prompt and laboratory experiments. One agent flagged an unusual repetitive pattern, triggering human review. Further analyses and laboratory tests led to the identification of an enzymatic system previously uncharacterized in bacteriophages.

First Result from the Biolab and Anthropic's Ambitions

This result constitutes the first achievement from Anthropic's new wet lab. The announcement comes as the company seeks to attract more scientists, aims to expand into drug discovery, and prepares for its IPO. More broadly, AI companies are increasingly turning to scientific research to demonstrate the value of their advanced models.